SEARCH:   Advanced

Blood, 1 June 2004, Vol. 103, No. 11, pp. 4028-4035. Prepublished online as a Blood First Edition Paper on February 19, 2004; DOI 10.1182/blood-2003-11-3929. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-11-3929v1 103/11/4028    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Miescher, S. Articles by Bichler, J. Search for Related Content PubMed PubMed Citation Articles by Miescher, S. Articles by Bichler, J. Related Collections Immunobiology Red Cells Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcRIIA and FcIIIA genes Sylvia Miescher, Martin O. Spycher, Hanspeter Amstutz, Masja de Haas, Marion Kleijer, Ulrich J. Kalus, Hartmut Radtke, Alphonse Hubsch, Irmgard Andresen, Roland M. Martin, and Johann Bichler From ZLB Bioplasma AG, Bern, Switzerland; the Institute of Immunology, Inselspital, Bern, Switzerland; Division CLB, Sanquin, Amsterdam, The Netherlands; and the Department of Transfusion Medicine, University Clinics Charité, Berlin, Germany. A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)–positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant anti-RhD effectively cleared RhD-positive RBCs after intravenous and intramuscular injection. The recombinant anti-RhD demonstrated a slower clearance rate compared with the polyclonal anti-RhD. There was no dose response, and there was considerable variation among subjects who received the same dose of recombinant anti-RhD. Interestingly, RhD-positive RBC clearance rates were strongly associated with Fc receptor IIA (FcRIIA) and FcIIIA but not with FcIIIB polymorphisms. Subjects homozygous for FcRIIA-131H or FcRIIIA-158V allotypes showed a faster clearance rate compared with both the heterozygote and the corresponding alternative homozygote allotypes. A similar but less marked trend was seen for the polyclonal anti-RhD. Despite the variation in clearance rates there was no evidence of anti-RhD alloantibodies in any of the subjects at +6 months after the RBC challenge. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies David Ternant, Marc Ohresser, Cécile Thomas, Guillaume Cartron, Hervé Watier, Gilles Paintaud, Alphonse Hubsch, Martin Spycher, Johann Bichler, and Sylvia Miescher Blood 2005 106: 1503-1505. [Full Text] [PDF] This article has been cited by other articles: P. Bruhns, B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daeron Specificity and affinity of human Fc{gamma} receptors and their polymorphic variants for human IgG subclasses Blood, April 16, 2009; 113(16): 3716 - 3725. [Abstract] [Full Text] [PDF] M. Shibata-Koyama, S. Iida, A. Okazaki, K. Mori, K. Kitajima-Miyama, S. Saitou, S. Kakita, Y. Kanda, K. Shitara, K. Kato, et al. The N-linked oligosaccharide at Fc{gamma}RIIIa Asn-45: an inhibitory element for high Fc{gamma}RIIIa binding affinity to IgG glycoforms lacking core fucosylation Glycobiology, February 1, 2009; 19(2): 126 - 134. [Abstract] [Full Text] [PDF] M. Kjaersgaard, R. Aslam, M. Kim, E. R. Speck, J. Freedman, D. I. H. Stewart, E. J. Wiersma, and J. W. Semple Epitope specificity and isotype of monoclonal anti-D antibodies dictate their ability to inhibit phagocytosis of opsonized platelets Blood, August 15, 2007; 110(4): 1359 - 1361. [Abstract] [Full Text] [PDF] K. L. Armour, D. R. Parry-Jones, N. Beharry, J. R. Ballinger, R. Mushens, R. K. Williams, C. Beatty, S. Stanworth, P. Lloyd-Evans, M. Scott, et al. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity Blood, April 1, 2006; 107(7): 2619 - 2626. [Abstract] [Full Text] [PDF] D. Ternant, M. Ohresser, C. Thomas, G. Cartron, H. Watier, G. Paintaud, A. Hubsch, M. Spycher, J. Bichler, and S. Miescher Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies Blood, August 15, 2005; 106(4): 1503 - 1505. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020